Y2X Life Sciences plans to utilize the core technology for applications such as portable units to diagnose COVID-19 from an individual's breath and aerosol detectors that monitor indoor air quality for the presence of SARS-CoV-2 in large gathering places such as airports, conference halls, government facilities, military installations and vessels and schools.
The licensed biosensor technology was developed in a multidisciplinary collaborative effort by researchers from the School of Medicine and McKelvey School of Engineering at Washington University in St. Louis.
The team was led by John Cirrito, PhD, associate professor of neurology, Carla Yuede, PhD, associate professor of psychiatry, and Rajan Chakrabarty, PhD, the Harold D. Jolley Career Development Associate Professor. Professor Chakrabarty also leads the University's Complex Aerosol Systems Research Laboratory.
The team was awarded a grant from the National Institutes of Health for the project through the RADx initiative (Rapid Acceleration of Diagnostics).
The core technology for the biosensor is based on research developed by Cirrito's laboratory that is currently used for Alzheimer's disease and brain metabolism research.
Headquartered in New York, Y2X Life Sciences is a company with a focus on effective and safe products to disrupt the transmission of infectious disease.
The company's vision is to ensure healthy environments, prevent future pandemics and give people confidence to move safely in the world.
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer